Suppression of IL-1β-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells

Condition tags

MeSH descriptors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (58)

• Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis via openalex
• Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters via openalex
• Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium via openalex
• Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis via openalex
• Effects of oxidants and antioxidants on proliferation of endometrial stromal cells via openalex
• Emerging drugs for endometriosis via openalex
• Endometriosis and Subfertility: Is the Relationship Resolved? via openalex
• Future Perspectives in the Medical Treatment of Endometriosis via openalex
• IL‐1β TNF‐α, and IL‐2 in Peritoneal Fluid and Macrophage‐Conditioned Media of Women With Endometriosis via openalex
• Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis? via openalex
• Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis? via openalex
• Inhibition of Proliferation of Endometrial Stromal Cells by Trichostatin A, RU486, CDB-2914, N-Acetylcysteine, and ICI 182780 via openalex
• Interleukin 1β, interleukin-6, and tumor necrosis factor-α in endometriotic tissue and in endometrium via openalex
• Is the dose to inhibit the COX-2 enzyme in nude mice also adequate in ‘human’ endometrial tissues? via openalex
• Medical Management of Endometriosis: Novel Targets and Approaches towards the Development of Future Treatment Regimes via openalex
• Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis via openalex
• Peritoneal Fluid lnterleukin‐1β and Tumor Necrosis Factor in Patients With Benign Gynecologic Disease via openalex
• Progestins for symptomatic endometriosis: a critical analysis of the evidence via openalex
• Promoter Hypermethylation of Progesterone Receptor Isoform B (PR-B) in Endometriosis via openalex
• Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis via openalex
• The potential danger of COX-2 inhibitors via openalex
• Treatment of Endometriosis via openalex
• W2125471714 via openalex
• W2136385901 via openalex
• W2143694424 via openalex
• W2148359829 via openalex
• W2152026308 via openalex
• W2158131645 via openalex
• W2158968701 via openalex
• W2159973565 via openalex
• W2322133447 via openalex
• W2409682597 via openalex
• W4211081176 via openalex
• W4255841728 via openalex
• W4285719527 via openalex
• W1965812853 via openalex
• W6669505957 via openalex
• W1969169755 via openalex
• W1987352835 via openalex
• W1993223905 via openalex
• W1994581608 via openalex
• W2007780460 via openalex
• W2021918003 via openalex
• W2024289681 via openalex
• W2026732117 via openalex
• W2032642844 via openalex
• W2035088045 via openalex
• W2039274017 via openalex
• W2040040765 via openalex
• W2040095832 via openalex
• W2049619918 via openalex
• W2058747197 via openalex
• W2068775998 via openalex
• W2087289721 via openalex
• W2097357124 via openalex
• W2102732690 via openalex
• W2109525253 via openalex
• W2109801386 via openalex

Cited by (38)

• The effects of endometrial polyps, leiomyomas, adenomyosis, and endometriosis on endometrial receptivity: phenotype, molecular pathways, and clinical implications 2026
• Aberrant expression of histone deacetylase 8 in endometriosis and its potential as a therapeutic target 2023
• Epigenetic Dysregulation in Endometriosis: Implications for Pathophysiology and Therapeutics 2023
• Corroborating evidence for aberrant expression of histone deacetylase 8 in endometriosis 2023
• Medical treatments of endometriosis: a review 2022
• Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology 2022
• Perioperative Suppression of Schwann Cell Dedifferentiation Reduces the Risk of Adenomyosis Resulting from Endometrial–Myometrial Interface Disruption in Mice 2022
• Deoxyribonucleic acid and chromatin imaging of endometriosis and endometrial carcinoma using atomic force microscopy 2019
• The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights 2019
• Effects of histone methyltransferase inhibition in endometriosis† 2018
• Current and emerging treatment options for endometriosis 2018
• Investigational drugs for the treatment of endometriosis, an update on recent developments 2018
• Epigenetic Drugs in the Treatment of Endometriosis 2018
• The promising role of placental growth factor in association with cyclooxygenase-2 as predictive markers for recurrent ovarian endometriosis 2017
• Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis 2016
• Platelets are an unindicted culprit in the development of endometriosis: clinical and experimental evidence 2015
• An overview of early drug development for endometriosis 2015
• Selective inhibition of prostaglandin E2 receptors EP2 and EP4 modulates DNA methylation and histone modification machinery proteins in human endometriotic cells 2015
• Potential New Drugs for Endometriosis: Experimental Evidence 2014
• Endometriosis 2013
• Valproic Acid and Progestin Inhibit Lesion Growth and Reduce Hyperalgesia in Experimentally Induced Endometriosis in Rats 2012
• Histone deacetylase inhibitors as therapeutics for endometriosis 2012
• The Epigenetics of Endometriosis 2012
• Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis 2012
• Interleukin-1β induces cyclooxygenase-2 expression and promotes the invasive ability of human mesenchymal stem cells derived from ovarian endometrioma 2011
• Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target 2011
• Pathogenesis: Epigenetics 2011
• Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis 2011
• The emerging role of epigenetics and miRNAs in endometriosis 2011
• Constitutive and Tumor Necrosis Factor-Alpha-Stimulated Activation of Nuclear Factor-KappaB in Immortalized Endometriotic Cells and Their Suppression by Trichostatin A 2010
• Suppression of migratory/invasive ability and induction of apoptosis in adenomyosis-derived mesenchymal stem cells by cyclooxygenase-2 inhibitors 2010
• Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice 2010
• Endometriosis 2009
• Cyclooxygenase-2 expression, Ki-67 labeling index, and perifocal neovascularization in endometriotic lesions 2009
• Emerging drugs for endometriosis 2008
• Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells 2008
• Cyclooxygenase-2 overexpression in ovarian endometriomas is associated with higher risk of recurrence 2008
• Trichostatin A, a Histone Deacetylase Inhibitor, Attenuates Invasiveness and Reactivates E-Cadherin Expression in Immortalized Endometriotic Cells 2007

Source provenance

europepmc

last seen: 2026-06-04T01:30:01.192114+00:00

openalex

last seen: 2026-06-04T00:00:01.174412+00:00

pubmed

last seen: 2026-05-13T22:15:00.519696+00:00